Compugen Ltd. Ordinary Shares (CGEN)

FairStock Score: 95/100 — HIGH CONVICTION

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable competitive advantages, honest earnings, and a margin of safety. Compugen does not fit that mold neatly. It is a clinical-stage biotech with 75 employees, developing immuno-oncology antibodies COM701 and COM902, both still in Phase 1. The moat, if any, is pipeline intellectual property and trial data, not a proven commercial franchise. The only filed operating period supplied is fiscal Q2 2026, when revenue was $2.6 million and net loss was $7.0 million, a negative margin of 269.25%. That is not a self-funding enterprise. The balance sheet looks low-leverage: D/E 0.03, while FairStock's ROE is 50.64% and ROCE is 15.46%. But FairStock's Piotroski F-Score is only 2/9 and Altman Z-Score is -0.62, warning of weak financial quality. At the 2026-10-13 close of $1.98, FairStock's P/E is 5.21, P/B is 2.11, Graham Number is $2.83, and margin of safety is 30.04%. EV/EBITDA is 9.00 and PEG is 1.14. Those are not obviously expensive, but a low P/E in a clinical-stage biotech can be fragile if losses recur. Beta is 2.79, and the 52-week range is $1.43-$3.24, which speaks to speculation. The computed Lynch category is none because there are only 0 years of filed results versus the 3 needed. I would treat this as a speculative pipeline bet, not a classic value compounder, and demand far more evidence of durable cash generation before calling it a bargain.

In plain English: Compugen is a small healthcare company that researches and develops cancer treatments. It is not yet consistently profitable: in fiscal Q2 2026 it had $2.6 million in revenue and lost $7.0 million. The share price looks lower than one conservative estimate of value, but the business is early-stage and financially fragile, so it is not clearly cheap or safe.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer